Augustine Asset Management Inc. bought a new position in Gilead Sciences, Inc. (NASDAQ:GILD) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 51,158 shares of the biopharmaceutical company’s stock, valued at approximately $4,144,000. Gilead Sciences accounts for about 2.6% of Augustine Asset Management Inc.’s holdings, making the stock its 12th biggest position.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Keel Point LLC increased its position in Gilead Sciences by 0.4% during the 2nd quarter. Keel Point LLC now owns 3,123 shares of the biopharmaceutical company’s stock valued at $221,000 after purchasing an additional 12 shares during the period. Paradigm Financial Advisors LLC increased its position in Gilead Sciences by 0.3% during the 2nd quarter. Paradigm Financial Advisors LLC now owns 8,723 shares of the biopharmaceutical company’s stock valued at $617,000 after purchasing an additional 26 shares during the period. West Oak Capital LLC increased its position in Gilead Sciences by 0.7% during the 2nd quarter. West Oak Capital LLC now owns 4,666 shares of the biopharmaceutical company’s stock valued at $330,000 after purchasing an additional 32 shares during the period. First Heartland Consultants Inc. increased its position in Gilead Sciences by 0.4% during the 2nd quarter. First Heartland Consultants Inc. now owns 8,927 shares of the biopharmaceutical company’s stock valued at $632,000 after purchasing an additional 39 shares during the period. Finally, Princeton Portfolio Strategies Group LLC increased its position in Gilead Sciences by 0.4% during the 2nd quarter. Princeton Portfolio Strategies Group LLC now owns 9,766 shares of the biopharmaceutical company’s stock valued at $691,000 after purchasing an additional 41 shares during the period. 75.94% of the stock is currently owned by institutional investors.

Gilead Sciences, Inc. (GILD) opened at $74.01 on Thursday. The stock has a market cap of $96,250.00, a PE ratio of 7.84, a P/E/G ratio of -1.26 and a beta of 1.13. Gilead Sciences, Inc. has a one year low of $63.76 and a one year high of $86.27. The company has a debt-to-equity ratio of 1.10, a current ratio of 3.68 and a quick ratio of 3.56.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.13 by $0.14. The company had revenue of $6.51 billion for the quarter, compared to analysts’ expectations of $6.40 billion. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. Gilead Sciences’s revenue was down 13.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.75 EPS. analysts expect that Gilead Sciences, Inc. will post 8.53 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Thursday, December 28th. Investors of record on Friday, December 15th will be paid a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a yield of 2.81%. The ex-dividend date is Thursday, December 14th. Gilead Sciences’s payout ratio is 23.66%.

GILD has been the topic of a number of research analyst reports. Argus raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $100.00 price objective on the stock in a research report on Thursday, August 31st. Deutsche Bank reissued a “buy” rating and set a $81.00 price objective on shares of Gilead Sciences in a research report on Thursday, August 31st. Vetr raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $91.98 price objective on the stock in a research report on Friday, October 13th. Credit Suisse Group reissued an “outperform” rating and set a $85.00 price objective (up from $79.00) on shares of Gilead Sciences in a research report on Tuesday, August 29th. Finally, Maxim Group reissued a “hold” rating on shares of Gilead Sciences in a research report on Monday, August 28th. One research analyst has rated the stock with a sell rating, thirteen have given a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $85.03.

In related news, EVP Gregg H. Alton sold 25,000 shares of the company’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $82.65, for a total value of $2,066,250.00. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider John C. Martin sold 73,333 shares of the company’s stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $74.98, for a total transaction of $5,498,508.34. Following the completion of the transaction, the insider now owns 3,070,099 shares in the company, valued at approximately $230,196,023.02. The disclosure for this sale can be found here. In the last quarter, insiders sold 494,999 shares of company stock worth $37,404,139. 1.30% of the stock is currently owned by company insiders.

TRADEMARK VIOLATION NOTICE: “Augustine Asset Management Inc. Takes Position in Gilead Sciences, Inc. (GILD)” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright law. The correct version of this report can be accessed at https://www.thecerbatgem.com/2017/12/21/augustine-asset-management-inc-takes-position-in-gilead-sciences-inc-gild.html.

Gilead Sciences Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Stock Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related stocks with our FREE daily email newsletter.